Good morning, ladies and gentlemen. Thank you for standing by, and welcome to BIO-key International’s Third Quarter 2020 Conference Call. During the presentation, all participants will be in listen-only mode. After the speakers’ remarks, you will be invited to participate in a question-and-answer session. As a reminder, this conference is being recorded today, Thursday, November 12, 2020. I’d now like to turn the conference over to Scott Mahnken, BIO-key’s Vice President of Channel Sales. Please begin.

Thank you for joining us this morning. With me today are BIO-key’s Chairman and CEO, Mike DePasquale; Fred Corsentino, our Chief Revenue Officer; and Ceci Welch, Chief Financial Officer. I’d like to remind everyone that today’s conference call and webcast may contain forward-looking statements that are subject to certain risks and uncertainties that may cause actual results to differ materially from those projected on the basis of these statements. The words project, estimate, intend, expect, anticipate, believe, plan, may, or will and similar expressions generally identify forward-looking statements. Such forward-looking statements are made based on management’s beliefs, as well as assumptions made and information currently available to management, pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. For a complete description of these and other risk factors that may affect the future performance of BIO-key International, see Risk Factors in the company’s Annual Report on Form 10-K and its other filings with the SEC. Listeners are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. The company also undertakes no obligation to disclose any revision to these forward-looking statements to reflect events or circumstances after the date made. And at this time, I’d like to turn the call over to Mike DePasquale. Mike?

Thank you, Scott, and good morning, everyone, and thank you for joining our call today. As we’ve all been dealing with the effects of coronavirus pandemic this past several months, I wanted to start off by thanking the entire BIO-key team, including our new colleagues at PistolStar for their hard work and commitment during these challenging times. I also want to congratulate Scott Mahnken, who just read our Safe Harbor statement for assuming the very important new role of Vice President of Channel Sales for BIO-key. Though, the COVID-19 pandemic continues to impact our business in a variety of ways, the third quarter was a pivotal period for BIO-key, as we not only completed the recapitalization of the company, but we were able to build revenue momentum particularly with our integrated PortalGuard solution. During the quarter, we began to see a gradual return to more normal sales and marketing dialogues. Though many of those are still remote meetings and many customer prospects have yet to fully reopen to IT event to dialogues, additionally, Q3 mark the first quarter incorporating the results of PistolStar and its PortalGuard multifactor, Identity and Access Management or IAM business. PortalGuard has proven to be an ideal solution for challenges created by the pandemic as businesses and institutions grappled to provide user-friendly remote access. In particular PortalGuard has demonstrated growing traction with higher education institutions sinking to strengthen and streamline online access to educational resources for students, faculty, and administration as these institutions manage the spike in remote access requirements. PortalGuard purchase formerly closed on June 30, the last day of Q2. And we made significant steps in advancing our strategic vision for the company during the third quarter. In July, we successfully recapitalized our company with the proceeds from a public offering of common stock…

Thank you, Mike. As Mike said, Q3 was a better quarter in terms of both sequential and year-over-year revenue improvement and was achieved despite many projects in our pipeline being postponed or pushed into 2021 due to the pandemic. We have made progress migrating to our 100% subscription model, which includes both SaaS or cloud-based offerings, as well as on-prem offerings. The PortalGuard SaaS platform is completed in Q3 with a strategic product launch that includes enterprise class, AWS, cloud infrastructure within a highly scalable system that is currently supporting over 35,000 end-users and can easily scale to support millions as we grow. We have many customers who are migrating to the SaaS platform, which is both better for customers budgeting and also provides BIO-key with an up-sell of stable recurring software revenue. We also better integrating our marketing and sales functions around three key verticals, education, financial services and government. Kim Johnson, who was previously mentioned, was appointed to head this effort to integrate the overall marketing plan, tailoring specific tactics within each sales vertical. For example, within the higher ed vertical, I know that one of Kim’s priorities is to target larger institutions. We really believed that given our recognition and current customer base, that we can become a more dominant player in this vertical. We also plan to target new partners, who align well vertically within each channel. In addition, we are also in the process of onboarding current Channel Alliance program partners to our PortalGuard platform under Scott’s direction, thereby expanding the potential reach of our solutions. We also hired a strategic accounts executive late last month. Obviously, we’re very excited about building the team as we believe there’s a large market opportunity, both in the U.S. and abroad. And we are working to extend our Channel Alliance program beyond the U.S. and Africa to the Asian Pacific region and the Middle East. On the last call, I said that we believe that the Pistol Star acquisition and the PortalGuard platform is a game changer for us. And you are just starting to see its impact in our revenue numbers and that trend should continue. Mind that with the exciting opportunity in Africa and we think we are set up well for 2021 and beyond as the pandemic receipts. We also think that the work from home and remote study are trends that will endure creating increased ID authentication and access management challenges that we are uniquely positioned to solve. With that, I’ll pass the call to Ceci for the financial review. Thank you.

Thank you, Fred. BIO-key’s Q3 2020 revenues increased to $943,000 from $453,000 in Q3 2019, mainly due to higher license and service fees related to the Pistol Star acquisition, which closed on June 30 and are included in the Q3 2020 results. Hardware sales decreased by $12,000 due to less hardware included in customer deployments and no orders for locks due to BIO-key’s exit from the retail lock business. For the nine months ended September 30, revenues increased to $1.77 million from $1.73 million during the comparable 2019 period, also primarily due to the higher license and service fees with the inclusion of the Pistol Star 2020 results, partially offset by the lower hardware sales. Gross margin improved to 78% Q3 2020 versus a negative gross margin in Q3 2019, primarily due to the non-cash software license amortization expense recorded in Q3 2019, which did not recur in Q3 2020. Adjusting for the software license amortization Q3 gross margin would have been approximately 50% on a comparable basis. Q3 2020 operating expenses included $1.8 million from $1.2 million in the partially – excuse me, with the increase, primarily reflecting the inclusion of the Pistol Star operating expenses in the consolidation. Higher expenses also included new marketing personnel website integration of Pistol Star and additional costs associated with Pistol Star office staff and other expenses and cost associated with the setup of the African subsidiary. Overall, BIO-key’s operating loss was reduced to $1.1 million in Q3 2020 versus $1.3 million in Q3 2019. Other expenses were $2.2 million in Q3 versus $558,000 in Q3 2019, primarily related to the amortization of the debt discount and debt issuance costs incurred as a result of the convertible debt financing. BIO-key resulted in that – resulted net loss available to stockholders of $3.3 million or $0.06 per share in Q3 2020 compared with $1.8 million or $0.13 per share for Q3 2019. For the first nine months of 2020, BIO-key reported a net loss available to shareholders of $8.4 million or $0.28 per share versus $5.1 million or $0.36 per share for the first nine months of 2019. In Q3, BIO-key completed the sale of common stock and warrants for the gross proceeds of $24.8 million, given the effect of the payment offering expenses and some accounts payable, as well as the retirement of $4.2 million of convertible notes. BIO-key has $18 million in cash and $235,000 to the note payable for the BIO-key – for the Pistol Star acquisition. With that overview, I can now turn the call back to the operator for the investor questions. Operator?

Thank you. At this time, we’ll begin the question-and-answer session. [Operator Instructions] Okay. Our first question comes from Jack Vander Aarde from Maxim Group. Please go ahead.

Great. Thank you. Good morning. Hi, Michael and hi team. Thanks for taking my questions. Let’s see. So, it’s good to see the strong revenue results that exceeded my expectations this quarter, looks like Pistol Star definitely contributed nicely to the results. Wondering if – I don’t believe you disclosed it, but wondering if you’re able to provide either an explicit or maybe a rough estimate of what Pistol Star contributed to 3Q revenue.

Ceci, I’ll turn that to you, what was the…

This was a part of 50-50 split in the quarter?

Okay. So 50-50, Jack.

50-50. Okay, that’s helpful. And then as you look at the next quarter here, obviously the elephants in the room here for you guys that could really move a needle, are these two large African contracts. And I appreciate the pretty granular update on the status of those. It’s encouraging to see that you expect one of them to start deployment and generate some revenues. Of the 650K of revenue, $650,000 expecting that one African contract in Q4, how much – how should I think about that at the segment level, in terms of the services revenue, licensing revenue and hardware? How would you expect that to be broken out just roughly?

Yes. Jack, good question. And it’s one that I think we’ve addressed before, as we indicated as we start much of what we do will be delivering hardware and deploying hardware and putting that into the hands of the resources on the ground there. So you can look to that to be dominantly hardware.

Got you. Okay. And then just curious, I don’t have as great of insight into how the deployment process and just deal with the whole plans are unraveling here. So just curious to know, why only 650K kind of revenue, initial hardware deployment, just relative to the $45 million opportunities, it’s such a minimal amount. So I’m just curious, what – why is it such a small piece upfront? Is that conservative too, it’s a room for upside there or is that just kind of was that expected?

It’s an initial startup. So it’s what we expected at the outset when we would begin deploying our hardware and our services. So we were expecting this to begin back in Q2, obviously things have slipped. So no, it was expected, it clearly in purely his startup.

Okay, understood. And then, I mean, do you have any insight maybe into just sticking with this particular contract, in terms of how the remainder of the revenue or the purchase order will be deployed or allocated throughout the quarters. Would you expect a sizable amount to then hit in Q1 2021 from that contract? Or is it really just still uncertain?

No, no. We expect the ramp to sequentially grow quarter-over-quarter. So as we get going, as we begin deploying, we expect that the ramp meaning the revenue each quarter out through 2022 is going to grow. Obviously, this is – a $45 million is a significant number. So we’re going to have to see a significant ramp in deployment and delivery each quarter going forward.

Okay, got it. That makes sense.

And let me – let me interject one other item. Hopefully, as we get to the end of the year, beginning of next year, we’ll be able to predict and to be able to provide some guidance as to the deployment schedules and then ultimately what the order and revenue impact will be. So I think, again, as we get through the end of this year, as we see things opening up, as we get more clarity on how things will proceed forward, we’ll be able to be more predictable. And with our PortalGuard business, as you know, it’s full and complete SaaS, and well, not – it’s full and complete subscription. Ultimately, as Fred described, we’re moving our customers to a SaaS platform. And right now we’re seeing great reception from our existing customers, as well as prospects. I think we’ll be much more predictable in 2021.

Okay, fantastic. And that makes sense too. As it relates to moving your customers to a SaaS subscription kind of model for PortalGuard, has the – were any of those actively converted and contributing to revenue in terms of like a SaaS revenue contribution or those – is that going to expect it to really be active in Q4?

No. As Fred described, we have customers on the SaaS platform. We have 35,000 end users that have been using the solution from the start of Q3 to the end of the quarter. So that’s going to continue to grow. This is in place and running and operating, and we expect that to grow dramatically.

Okay, great, fantastic. And then if we just remove the – when I’m looking at the fourth quarter here and giving your comments, you’re very positive on your outlook of the – I think the overall business is, fair to say. So if I exclude the 650,000 you’re embedding from this Africa contract, would you still – what’s your confidence level or uncertainty and outlook on the non-Africa related revenue. Would that be up – how confident are you that would be up Q over Q, year-over-year in Q4?

Highly confident.

Got it. Okay, great. And then just lastly, maybe just a quick question for Ceci, because I didn’t see the – I don’t think the 10-Q is out yet. Do you have the stock-based comp number on hand for the third quarter?

I believe that was around $30,000 for this third quarter.

The total stock comp.

Yes.

Got it, fantastic. All right. Michael, I appreciate the update. Ceci, thank you for the data point. It’s great to see the momentum building. It sounds like deployment of these major needle moving contracts is finally on its way. So congrats on the progress update and I’ll hop back in the queue.

Thank you, Jack.

[Operator Instructions] There are no questions in the queue. This concludes our question-and-answer session. I’ll turn the call back over to Mike DePasquale for closing remarks.

Great. First, I want to thank everyone for participating in today’s call. We look forward to updating you on our next quarterly call. And of course, we’ll continue to provide interim news updates and reports as warranted. Thank you, everyone. Stay safe, and stay healthy.

The conference is now concluded. Thank you for attending today’s presentation. You may now disconnect.